Gilead Sciences and Sovaldi : the cost of a cure (B) / Benjamin Budish, Chase Lane, Richard Zaleski, James S. O'Rourke.
Gilead Sciences hepatitis C drug, Sovaldi, proved more effective than the competition and was priced in line with market conditions. However, extremely high cost and large patient population captured the attention of the media, the public, NGOs, and even the government. The controversy deepened when...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Ebook |
| Language: | English |
| Published: |
London :
SAGE Publications Ltd,
2017.
|
| Series: | SAGE Knowledge. Cases.
|
| Subjects: | |
| Online Access: | SAGE |
MARC
| LEADER | 00000czm a22000004i 4500 | ||
|---|---|---|---|
| 003 | OCoLC | ||
| 005 | 20221110070904.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 170109r20172014enk fo 000 0 eng d | ||
| 011 | |a Direct search result | ||
| 011 | |a EDS Title: Gilead Sciences and Sovaldi: The Cost of a Cure (B) | ||
| 011 | |a MARC Score : 10450(21500) : OK | ||
| 020 | |a 1526403129 |q Internet | ||
| 020 | |a 9781526403124 |q Internet | ||
| 035 | |a (OCoLC)1017732847 | ||
| 035 | |a (EDS)EDS12224276 | ||
| 040 | |a SGPBL |b eng |e rda |c SGPBL |d OCLCO |d OCLCF |d OCLCA |d ATU | ||
| 050 | 4 | |a HF5387 |b .B83 2017 | |
| 082 | 0 | 4 | |a 174.4 |
| 100 | 1 | |a Budish, Benjamin, |e author. | |
| 245 | 1 | 0 | |a Gilead Sciences and Sovaldi : |b the cost of a cure (B) / |c Benjamin Budish, Chase Lane, Richard Zaleski, James S. O'Rourke. |
| 264 | 1 | |a London : |b SAGE Publications Ltd, |c 2017. | |
| 300 | |a 1 online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a SAGE Knowledge. Cases | |
| 500 | |a Originally published in Budish, B., Lane, C., Zaleski, R., & ORourke, J. S. (2014). Gilead Sciences and Sovaldi: The cost of a cure (B). 14-10 (B). Notre Dame, IN: The Eugene D. Fanning Center for Business Communication, Mendoza College of Business, University of Notre Dame. | ||
| 520 | 8 | |a Gilead Sciences hepatitis C drug, Sovaldi, proved more effective than the competition and was priced in line with market conditions. However, extremely high cost and large patient population captured the attention of the media, the public, NGOs, and even the government. The controversy deepened when the company revealed the cost in developing countries would be roughly 1% of the cost in the U.S. | |
| 588 | |a Description based on XML content. | ||
| 610 | 2 | 0 | |a Gilead Sciences (Firm) |9 486034 |
| 650 | 0 | |a Business ethics. |9 345455 | |
| 650 | 0 | |a Strategic planning. |9 345424 | |
| 650 | 0 | |a Pharmaceutical industry. |9 316859 | |
| 700 | 1 | |a Lane, Chase, |e author. | |
| 700 | 1 | |a Zaleski, Richard, |e author. | |
| 700 | 1 | |a O'Rourke, James S., |d 1946- |e author. |9 419570 | |
| 776 | 1 | 8 | |w (OCoLC)1058900838 |
| 830 | 0 | |a SAGE Knowledge. |p Cases. | |
| 856 | 4 | 0 | |u https://ezproxy.aut.ac.nz/login?url=https://sk.sagepub.com/cases/gilead-sciences-and-sovaldi-the-cost-of-a-cure-b |z SAGE |x TEMPORARY ERM URL |
| 907 | |a .b27154774 |b 06-09-21 |c 02-08-19 | ||
| 942 | |c EB | ||
| 998 | |a none |b 02-08-19 |c m |d z |e - |f eng |g enk |h 0 | ||
| 999 | |c 1510042 |d 1510042 | ||